Le Lézard
Classified in: Health
Subjects: MISCELLANEOUS, MISCELLANEOUS, MISCELLANEOUS

Clifford Sarkin Appointed to Millennium BlockChain Board of Advisors


SANTA MONICA, CA, March 14, 2018 (GLOBE NEWSWIRE) -- Millennium BlockChain Inc. (OTC:MBLC; the "Company") is pleased to announce that Clifford Sarkin has joined the Company's board of advisors.

Sarkin is a strategic advisor to technology leaders of major blockchain and cryptocurrency projects. An attorney and seasoned executive, Sarkin has deep expertise in emerging technologies, corporate law, transactions, M&A, private equity and venture capital. Sarkin is currently a Venture Partner with DNA, one of the world's leading crypto venture capital funds.

Prior to his work with distributed ledger technologies, Sarkin served as legal counsel and business operations executive for three internet startups in the San Francisco Bay Area and Los Angeles. Among several notable accomplishments, Sarkin led VideoSurf's $80M cash acquisition by Microsoft in 2011. Sarkin received his J.D. from Harvard Law School ('05), his B.A. in Political Science from UC Berkeley ('01) and is licensed to practice law in the state of California.

"It is an honor for me to join Millennium BlockChain's board of advisors," said Sarkin. "MBLC is uniquely positioned to identify and help grow some of the industry's most promising and impactful companies. I look forward to the opportunity to support Millennium BlockChain's impressive team on this journey."

"Clifford Sarkin has developed a keen eye for spotting and cultivating great opportunities in the blockchain ecosystem," said Enzo Villani, Chairman of Millennium BlockChain. "As we continue to fill out the team, we are focused on investing in top blockchain projects."

"The addition of Cliff Sarkin to our board of advisors is another step toward building a great team at Millennium BlockChain," said Brandon Romanek, CEO of Millennium BlockChain. "Alongside the recent additions of Cory Klippsten, formerly of Google, McKinsey and Microsoft, and Michael Terpin, currently of the Transform Group, Cliff's vast experience as an adviser to some of the world's top blockchain projects will benefit us greatly."

The Millennium BlockChain advisory board will assist the Company's management team to source, review, and consider blockchain technologies and strategic partnerships for the Company. The advisory board will also provide additional ideas and support for new developments, as well as assist in outlining the strategic direction of the Company.

About Millennium BlockChain
Millennium BlockChain, (OTC:MBLC), is a holding company primarily focused on blockchain technologies and crypto-assets in financial markets, healthcare, crypto-mining and high technology sectors. For more information, please visit www.mblockchain.io

Millennium BlockChain Media Contact:
Transform Group, [email protected]

Millennium BlockChain Investors Contact:
[email protected], (702) 602-8422

Safe Harbor Statement
This press release may contain "forward-looking statements" within the meaning of the federal securities laws. In this context, forward-looking statements may address the Company's expected future business and financial performance, and often contain words such as "anticipates", "beliefs", "estimates", "expects", "intends", "plans", "seeks", "will", and other terms with similar meaning. These forward-looking statements by their nature address matters that are, to different degrees, uncertain. Although the Company believes that the assumptions upon which its forward-looking statements based are reasonable, it can provide no assurances that these assumptions will prove to be correct. All forward-looking statements in this press release are expressly qualified by such cautionary statements, risk, and uncertainties, and by reference to the underlying assumptions. 


These press releases may also interest you

at 23:33
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

at 22:54
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

at 22:03
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

at 20:35
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

at 19:05
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIOŽ (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...

at 18:42
The Honourable Ya'ara Saks, Minister of Mental Health and Addictions and Associate Minister of Health, will host an event at the University of Manitoba to highlight the federal budget's investments to boost funding for research in Canada. A media...



News published on and distributed by: